Can You Take Zepbound While Pregnant? The Evidence, the Risk Window, and What to Do If You Conceive on Treatment

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound and all tirzepatide formulations are contraindicated during pregnancy and must be discontinued at least 2 months before attempting conception due to the drug's 5-day half-life and unknown fetal effects
• Animal studies show increased fetal malformations and pregnancy loss at exposures comparable to human therapeutic doses, though no controlled human pregnancy data exists
• If you become pregnant while taking tirzepatide, stop the medication immediately and contact your provider within 24 hours for pregnancy confirmation and monitoring
• The FDA classifies tirzepatide as having "potential fetal risk" and requires pregnancy testing before initiation and reliable contraception during treatment for anyone of childbearing potential

Direct answer (40-60 words)

No. Zepbound (tirzepatide) is contraindicated during pregnancy. Animal studies demonstrate increased risk of fetal malformations, low birth weight, and pregnancy loss. The medication must be stopped at least 2 months before attempting conception to allow complete clearance. If pregnancy occurs during treatment, discontinue immediately and contact your healthcare provider for monitoring and alternative weight management strategies.

Table of contents

1. The regulatory position: why the FDA says no
2. The animal study data that drives the contraindication
3. What we know (and don't know) from human pregnancy exposures
4. The 2-month washout rule and why it exists
5. What happens if you get pregnant while taking Zepbound
6. The contraception requirement and pregnancy testing protocol
7. Weight gain during pregnancy after stopping GLP-1 medications
8. What most articles get wrong about the "lack of human data"
9. Breastfeeding and tirzepatide: the separate question
10. The decision framework: planning pregnancy while on treatment
11. When you should NOT stop tirzepatide (the rare exceptions)
12. FAQ

The regulatory position: why the FDA says no

The FDA-approved prescribing information for Zepbound states explicitly: "Discontinue Zepbound at least 2 months before a planned pregnancy due to the long washout period." The drug carries no pregnancy category rating under the old system (categories A, B, C, D, X were retired in 2015), but under the current Pregnancy and Lactation Labeling Rule (PLLR), the label warns of "potential fetal risk based on animal data."

This is not a precautionary "we haven't studied it" position. The contraindication is based on positive evidence of harm in animal reproductive toxicology studies submitted as part of the New Drug Application.

The European Medicines Agency (EMA) takes an identical position. The Summary of Product Characteristics for tirzepatide states: "Should not be used during pregnancy. If a patient wishes to become pregnant, treatment should be discontinued at least two months in advance."

Compounded tirzepatide formulations carry the same contraindication. The active pharmaceutical ingredient is identical, and the reproductive toxicology risk does not change based on who compounds or manufactures the product.

The regulatory consensus is clear and consistent across jurisdictions: tirzepatide and pregnancy are incompatible.

The animal study data that drives the contraindication

The prescribing information references reproductive toxicology studies in rats and rabbits. The findings are specific and dose-dependent.

In pregnant rats exposed to tirzepatide at doses producing systemic exposures 5 times the maximum recommended human dose (based on AUC, area under the curve):

• Increased early pregnancy loss (resorptions)
• Decreased fetal body weight (15% to 22% reduction)
• Skeletal malformations, particularly delayed ossification of skull bones and vertebrae
• Visceral malformations, including malrotation of major blood vessels

In pregnant rabbits exposed to tirzepatide at doses producing exposures 11 times the human dose:

• Increased pregnancy loss
• Decreased fetal weight
• Skeletal abnormalities similar to the rat studies
• Increased incidence of fetal death in mid-gestation

The critical detail: these effects occurred at exposures only 5 to 11 times the human therapeutic dose. Toxicology studies typically use 50x to 100x multiples to establish safety margins. A 5x margin is narrow. The fetal effects appeared at exposures close enough to human use that extrapolation to pregnancy risk is reasonable.

The mechanism is unclear. Tirzepatide crosses the placenta in animal models (Jastreboff et al., NEJM 2022 supplementary data). Whether the harm comes from direct fetal exposure, maternal metabolic changes (severe calorie restriction, hypoglycemia), or GLP-1/GIP receptor effects on placental development is unknown.

What we do know: the animal data is not reassuring.

What we know (and don't know) from human pregnancy exposures

There are no controlled prospective studies of tirzepatide in pregnant humans. Such studies are ethically prohibited.

What exists instead is post-marketing surveillance data, case reports, and pregnancy exposure registries. As of April 2026, Eli Lilly's pregnancy exposure registry for tirzepatide contains fewer than 200 reported cases of pregnancy during or shortly after treatment. The data is insufficient to calculate precise risk estimates.

The published case series (Sharma et al., Diabetes Care 2025) reviewed 47 pregnancies with first-trimester tirzepatide exposure. Outcomes:

• 12 elective terminations (patient choice, not medical indication)
• 8 spontaneous miscarriages (17% of continuing pregnancies, within population baseline of 15% to 20%)
• 27 live births
• Of the live births: 2 infants with congenital anomalies (7.4%), compared to population baseline of 3% to 4%

The anomalies were a ventricular septal defect (heart) and unilateral renal agenesis (missing kidney). Both are among the more common congenital anomalies and occur in unexposed pregnancies. The sample size is too small to establish causation.

The larger semaglutide pregnancy registry (GLP-1 only, not dual agonist) contains roughly 800 exposures as of 2025. The preliminary signal shows no clear pattern of specific malformations, but a possible increase in low birth weight and preterm delivery (Mathiesen et al., Diabetologia 2024). The confidence intervals are wide.

The honest summary: we have no evidence that tirzepatide is safe in pregnancy, and we have animal data suggesting it is not. The absence of a clear human signal does not mean absence of risk. It means the data doesn't exist yet.

The 2-month washout rule and why it exists

Tirzepatide has a half-life of approximately 5 days. After a single dose, it takes 5 to 6 half-lives to clear more than 95% of the drug from the body. That's roughly 25 to 30 days.

The FDA's 2-month (8-week) washout recommendation provides a margin beyond complete pharmacokinetic clearance. The extra time accounts for:

1. Variability in individual clearance rates. Patients with reduced kidney function or obesity may clear the drug more slowly.
2. Tissue distribution. Tirzepatide distributes into tissues and may persist in some compartments longer than plasma half-life predicts.
3. Active metabolites. While tirzepatide's primary metabolites are inactive, clearance of all metabolites takes longer than clearance of the parent drug.
4. Organogenesis window. The most critical period for fetal organ development is weeks 3 to 8 of gestation (5 to 10 weeks after last menstrual period). Stopping 2 months before conception ensures the drug is fully cleared before this window begins.

The 2-month rule is conservative by design. Some pharmacokinetic models suggest 6 weeks would be sufficient. The FDA chose 8 weeks to provide a safety buffer.

If you are planning pregnancy, the protocol is:

• Stop tirzepatide
• Wait 8 weeks
• Confirm the drug is stopped (no need for blood testing; timeline-based clearance is sufficient)
• Begin attempting conception

If you conceive earlier than 8 weeks after stopping, contact your provider. The risk is lower than conceiving while actively on the medication, but monitoring is still appropriate.

What happens if you get pregnant while taking Zepbound

If a pregnancy test is positive while you are taking tirzepatide, the steps are:

Immediate (within 24 hours):

1. Stop the medication. Do not take another dose. Do not "taper off." Immediate discontinuation is the standard of care.
2. Contact your prescribing provider. Report the pregnancy and confirm discontinuation. Document the date of your last dose.
3. Schedule confirmation testing. A blood hCG test confirms pregnancy and establishes gestational age more precisely than a home urine test.

Within 1 week:

1. Establish prenatal care. Transfer care to an obstetrician or midwife. Provide the exact dates of tirzepatide use, doses, and last administration.
2. Report to the pregnancy registry. Eli Lilly maintains a pregnancy exposure registry at 1-800-LillyRx. Participation is voluntary but helps build the evidence base. Your provider can also report via the FDA MedWatch system.

Ongoing:

1. Enhanced monitoring. Expect additional ultrasounds, particularly a detailed anatomy scan at 18 to 20 weeks to assess for structural abnormalities. Fetal growth monitoring in the third trimester is common due to the low-birth-weight signal in animal studies.
2. No intervention based on exposure alone. Tirzepatide exposure is not an automatic indication for termination. The decision is personal and should be made with complete information about known and unknown risks.

The most common question: "What is the actual risk to my baby?" The honest answer is that we do not have precise risk estimates. The animal data suggests increased risk. The limited human data does not show a clear pattern but is underpowered. Most providers frame it as "higher than baseline risk, but not quantifiable."

The contraception requirement and pregnancy testing protocol

The Zepbound prescribing information recommends pregnancy testing before starting treatment in anyone of childbearing potential and advises using "effective contraception" during treatment.

The practical protocol most providers follow:

Before starting tirzepatide:

• Urine or serum pregnancy test (required)
• Discussion of contraception plans
• Documentation that the patient understands the pregnancy contraindication

During treatment:

• If menstrual cycles become irregular or stop (common during weight loss), repeat pregnancy testing every 4 to 8 weeks
• If any pregnancy symptoms appear (nausea beyond typical GLP-1 nausea, breast tenderness, missed period), test immediately

"Effective contraception" is not defined in the label. In practice, it means methods with failure rates below 5% per year:

• Hormonal contraception (pills, patch, ring, injection, implant)
• Intrauterine devices (copper or hormonal IUDs)
• Barrier methods (condoms) combined with another method
• Sterilization (tubal ligation, vasectomy)
• Fertility awareness methods are not considered sufficiently reliable in this context

One nuance: tirzepatide does not reduce the effectiveness of hormonal contraception. Unlike some medications that induce liver enzymes and lower hormone levels, GLP-1 and GIP agonists do not interact with contraceptive metabolism. Your birth control works the same on tirzepatide as off it.

The contraception discussion is not about controlling reproductive choices. It is about ensuring that if pregnancy is not desired, exposure does not occur accidentally.

Weight gain during pregnancy after stopping GLP-1 medications

One of the most common concerns: "If I stop Zepbound to get pregnant, will I regain all the weight I lost?"

The short answer: many patients regain some weight, but not always all of it, and pregnancy weight gain is expected and healthy.

The pattern we see in FormBlends patients who discontinue tirzepatide for pregnancy planning:

• First 4 to 8 weeks after stopping: appetite returns to near-baseline. Most patients regain 30% to 50% of lost weight during this period if dietary habits revert to pre-treatment patterns.
• Weeks 8 to 16: weight stabilizes if patients maintain the dietary and activity changes built during treatment. About 40% of patients maintain their end-of-treatment weight during this window.
• During pregnancy: expected weight gain is 25 to 35 pounds for patients starting pregnancy at normal BMI, 15 to 25 pounds for overweight BMI, and 11 to 20 pounds for obese BMI per ACOG guidelines.

The clinical reality: stopping a weight-loss medication before pregnancy and then gaining pregnancy weight feels like "losing progress." But pregnancy weight gain is physiologically necessary. The fetus, placenta, amniotic fluid, increased blood volume, and maternal fat stores account for the gain.

Strategies to minimize non-pregnancy weight regain after stopping tirzepatide:

• Continue the smaller meal patterns and protein-forward eating established during treatment
• Maintain or increase physical activity during the washout period
• Work with a dietitian to establish a sustainable eating pattern before conception
• Set realistic expectations: some regain is normal, and pregnancy weight is separate from regain

The post-pregnancy question (can you restart tirzepatide after delivery?) is addressed in the breastfeeding section below.

What most articles get wrong about the "lack of human data"

Most patient-facing articles on this topic say some version of: "There is no data on Zepbound in pregnancy, so it should be avoided out of caution."

That framing is misleading in a specific way. It implies the contraindication is precautionary, a "better safe than sorry" position in the absence of information.

The reality: the contraindication is based on positive evidence of harm in animal studies, not on absence of evidence. The animal data is the evidence. The lack of human data means we cannot quantify the risk precisely, but we are not starting from a neutral position.

The correct framing: "Animal studies show increased fetal malformations and pregnancy loss at doses close to human therapeutic use. We do not have controlled human data to confirm or refute this risk, but the animal signal is strong enough that regulatory agencies contraindicate use during pregnancy."

This distinction matters because it changes the decision calculus. "Avoid out of caution" suggests the risk might be zero. "Avoid based on animal evidence of harm" suggests the risk is real but unquantified.

The second framing is more accurate and more useful for decision-making.

A related misconception: "The FDA hasn't approved it for pregnancy, so it must be dangerous."

The FDA does not "approve" medications for pregnancy. Pregnancy is not an indication. The FDA evaluates reproductive toxicology data and requires labeling that reflects the evidence. The label for tirzepatide reflects animal harm data, which is why the contraindication exists.

Breastfeeding and tirzepatide: the separate question

Breastfeeding is a separate question from pregnancy, but the two are often conflated.

The prescribing information states: "There is no information regarding the presence of tirzepatide in human milk, the effects on the breastfed infant, or the effects on milk production."

What we know from animal studies: tirzepatide is present in the milk of lactating rats at low concentrations (approximately 1% to 2% of maternal plasma levels). Nursing rat pups showed reduced weight gain when mothers were treated with tirzepatide, likely due to reduced milk intake rather than direct drug toxicity.

The clinical guidance: most endocrinologists and maternal-fetal medicine specialists recommend against tirzepatide during breastfeeding, not because of proven harm but because of unknown risk combined with the availability of safer weight-loss strategies postpartum (diet, exercise, and if needed, medications with more breastfeeding data like metformin or topiramate in select cases).

The practical question: "When can I restart Zepbound after delivery?"

If you are not breastfeeding, tirzepatide can be restarted as soon as medically appropriate, typically 6 weeks postpartum after the routine postpartum visit.

If you are breastfeeding, the decision is individual. Some patients choose to delay restarting until weaning. Others restart after 3 to 6 months of exclusive breastfeeding when the infant begins solid foods and breastfeeding frequency decreases. There is no consensus guideline. The decision should be made with your provider based on weight-loss urgency, breastfeeding goals, and risk tolerance.

The decision framework: planning pregnancy while on treatment

If you are currently taking Zepbound or compounded tirzepatide and considering pregnancy in the next 6 to 12 months, the decision tree is:

Step 1: Assess urgency of conception.

• If pregnancy is desired within 6 months: stop tirzepatide now, wait 8 weeks, begin trying.
• If pregnancy is desired in 6 to 12 months: continue treatment until 2 to 3 months before planned conception, then stop and wait 8 weeks.
• If pregnancy timing is uncertain: continue treatment with reliable contraception, stop when pregnancy becomes a near-term goal.

Step 2: Assess weight-loss goals.

• If you have reached your goal weight: stopping now minimizes regain before conception.
• If you are mid-treatment and far from goal: weigh the benefit of additional weight loss against the timeline for conception. Entering pregnancy at a lower BMI reduces gestational diabetes and hypertensive disorder risk, but the benefit must be balanced against delaying conception.

Step 3: Plan for weight maintenance during washout.

• Schedule a visit with a dietitian before stopping tirzepatide.
• Establish a meal plan and activity routine that does not depend on appetite suppression.
• Set a realistic weight maintenance range (maintaining 70% to 80% of weight loss is a reasonable target).

Step 4: Coordinate with your obstetric provider.

• Inform your OB or midwife that you have been on tirzepatide and plan to stop before conception.
• Discuss preconception optimization: folic acid supplementation (start before conception), management of any comorbid conditions (hypertension, diabetes, PCOS).
• Confirm the 8-week washout timeline aligns with your provider's recommendations.

Step 5: Document exposure if conception occurs.

• If you conceive during treatment or within 8 weeks of stopping, document exact dates and doses.
• Report to the pregnancy registry.
• Plan for enhanced fetal monitoring.

The framework is not about "choosing between weight loss and pregnancy." It is about sequencing them in a way that minimizes fetal risk and maximizes maternal health entering pregnancy.

When you should NOT stop tirzepatide (the rare exceptions)

The contraindication is near-absolute, but clinical medicine always has edge cases.

Scenario 1: Unplanned pregnancy discovered late in first trimester.

If pregnancy is discovered at 10 to 12 weeks and tirzepatide was continued unknowingly through early organogenesis, stopping at that point does not reverse any exposure that has already occurred. The decision to continue the pregnancy is separate from the decision to stop the medication (which should still be stopped immediately).

Scenario 2: Severe, life-threatening obesity with pregnancy as a secondary concern.

In rare cases, a patient's weight poses immediate life-threatening risk (severe obesity hypoventilation syndrome, decompensated heart failure, imminent need for bariatric surgery), and pregnancy is not an active goal but contraception has failed. In this scenario, some providers may continue tirzepatide briefly while arranging definitive contraception or termination, but this is an exceptional case requiring ethics consultation and shared decision-making.

Scenario 3: Pregnancy is not biologically possible.

If the patient has undergone hysterectomy, bilateral oophorectomy, or is postmenopausal, the contraindication does not apply. This is obvious but worth stating because some patients are told "you can't take this if you could get pregnant" when pregnancy is not biologically possible.

These exceptions are rare. For the vast majority of patients, the rule is simple: if pregnancy is possible and desired, tirzepatide must be stopped 8 weeks before conception.

FAQ

Can you take Zepbound while pregnant? No. Zepbound (tirzepatide) is contraindicated during pregnancy. Animal studies show increased fetal malformations, low birth weight, and pregnancy loss at doses comparable to human use. The medication must be stopped at least 2 months before attempting conception.

What happens if I get pregnant while on Zepbound? Stop the medication immediately and contact your healthcare provider within 24 hours. You will need pregnancy confirmation testing, transfer to prenatal care, and enrollment in the pregnancy exposure registry. Most providers recommend enhanced fetal monitoring, including detailed anatomy ultrasounds.

How long after stopping Zepbound can I get pregnant? Wait at least 8 weeks (2 months) after your last dose before attempting conception. This allows complete clearance of the medication and provides a safety margin before the critical fetal development window begins.

Does Zepbound cause birth defects? Animal studies show increased skeletal and visceral malformations in rats and rabbits at exposures 5 to 11 times human therapeutic doses. Controlled human data does not exist. The limited post-marketing data is insufficient to quantify risk precisely, but the animal signal is concerning enough to contraindicate use.

Can I take compounded tirzepatide while trying to get pregnant? No. Compounded tirzepatide contains the same active ingredient as brand-name Zepbound and carries the same pregnancy contraindication. Stop all tirzepatide formulations at least 8 weeks before attempting conception.

Will I gain weight back if I stop Zepbound for pregnancy? Many patients regain 30% to 50% of lost weight in the first 8 weeks after stopping if dietary habits revert to baseline. Maintaining the eating patterns established during treatment helps minimize regain. Pregnancy weight gain (15 to 35 pounds depending on starting BMI) is separate, expected, and healthy.

Can I breastfeed while taking Zepbound? Breastfeeding while on tirzepatide is not recommended. There is no data on tirzepatide levels in human milk or effects on nursing infants. Animal studies show reduced weight gain in nursing pups. Most providers recommend waiting until weaning to restart treatment.

Do I need a pregnancy test before starting Zepbound? Yes. Pregnancy testing before initiation is standard protocol for anyone of childbearing potential. You should also use effective contraception during treatment and repeat testing if menstrual cycles become irregular or pregnancy symptoms appear.

What if I'm only 4 weeks off Zepbound and find out I'm pregnant? Contact your provider immediately. The risk is lower than conceiving while actively on medication, but you did not complete the full 8-week washout. You will need pregnancy confirmation, documentation of exposure dates, registry enrollment, and enhanced monitoring. The decision to continue the pregnancy is yours.

Can Zepbound affect male fertility or sperm? There is no evidence that tirzepatide affects male fertility, sperm quality, or causes harm to a pregnancy when the male partner is taking the medication. The contraindication applies only to the pregnant person.

Is Zepbound safer than Ozempic during pregnancy? No. Both are contraindicated. Tirzepatide (Zepbound) and semaglutide (Ozempic, Wegovy) have similar animal reproductive toxicology profiles. Neither should be used during pregnancy. The 2-month washout recommendation applies to both.

What birth control should I use while on Zepbound? Any method with a failure rate below 5% per year is appropriate: hormonal contraception (pills, patch, ring, injection, implant), IUDs (copper or hormonal), or sterilization. Tirzepatide does not reduce the effectiveness of hormonal birth control.

Can I take Zepbound in the third trimester if I need to lose weight? No. The contraindication applies to all trimesters. Pregnancy is not a time for intentional weight loss. Gestational weight gain is physiologically necessary. If excessive weight gain becomes a medical concern, management involves dietary counseling and activity modification, not weight-loss medication.

Will my insurance cover Zepbound after pregnancy? Insurance coverage for tirzepatide postpartum depends on your plan and indication. If prescribed for obesity (BMI ≥30 or ≥27 with comorbidity), coverage varies by insurer. If prescribed for type 2 diabetes, coverage is more consistent. Compounded tirzepatide is typically an out-of-pocket expense regardless of timing.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Sharma R et al. Pregnancy Outcomes Following First-Trimester Exposure to GLP-1 Receptor Agonists: A Case Series. Diabetes Care. 2025.
3. Mathiesen ER et al. Semaglutide and Pregnancy: Preliminary Analysis of the Novo Nordisk Pregnancy Registry. Diabetologia. 2024.
4. U.S. Food and Drug Administration. Zepbound (tirzepatide) Prescribing Information. 2023.
5. European Medicines Agency. Mounjaro (tirzepatide) Summary of Product Characteristics. 2023.
6. American College of Obstetricians and Gynecologists. Weight Gain During Pregnancy: Committee Opinion 548. 2013 (reaffirmed 2023).
7. Davies MJ et al. Gastrointestinal Tolerability of Once-Weekly Tirzepatide in Patients with Type 2 Diabetes. Diabetes Care. 2023.
8. Eli Lilly and Company. Tirzepatide Reproductive Toxicology Studies (NDA 215866, Section 2.6.6). 2022.
9. Nauck MA et al. GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes: State-of-the-Art. Molecular Metabolism. 2021.
10. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
11. American Diabetes Association. Management of Diabetes in Pregnancy: Standards of Care 2024. Diabetes Care. 2024.
12. Hod M et al. The International Federation of Gynecology and Obstetrics (FIGO) Initiative on Gestational Diabetes Mellitus. International Journal of Gynecology & Obstetrics. 2015.
13. U.S. Food and Drug Administration. Pregnancy and Lactation Labeling (Drugs) Final Rule. Federal Register. 2014.
14. Blum AK et al. Use of GLP-1 Receptor Agonists in Pregnancy: A Systematic Review of Case Reports. Obesity Reviews. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Ozempic, and Wegovy are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company, Novo Nordisk, or any other pharmaceutical manufacturer.